ArticleNeurology2015
Optimal combination secondary prevention drug treatment and stroke outcomes.
Article in Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis.PloS one · 2019Pooled it
- Effect of Colchicine for Prevention of Recurrent Stroke in Ischemic Stroke Patients with Atrial Fibrillation: A Randomized Double-blinded Placebo-controlled Trial.Reviews on recent clinical trials · 2025Trial
- A cardiovascular polypill for secondary stroke prevention in a tertiary centre in Ghana (SMAART): a phase 2 randomised clinical trial.The Lancet. Global health · 2023Trial
- Age and Sex Disparities in Discharge Statin Prescribing in the Stroke Belt: Evidence From the Reasons for Geographic and Racial Differences in Stroke Study.Journal of the American Heart Association · 2017Trial
- Stroke minimization through additive anti-atherosclerotic agents in routine treatment (SMAART) II: Rationale for a multi-country polypill phase 3 trial in sub-Saharan Africa.Equity neuroscience · 2026Article
- Pharmacist-Led Patient Education in Secondary Stroke Prevention: A Systematic Review.The Malaysian journal of medical sciences : MJMS · 2025Review
- Beyond boundaries: Neuroprotective effects of steroids and ecdysteroids in SH-SY5Y cells - A systematic review.Neuroprotection (Chichester, England) · 2024Review
- Article
- Overview of Acute Ischemic Stroke Evaluation and Management.Biomedicines · 2021Review
- Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack.Stroke and vascular neurology · 2021Article
- Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack.BMC medicine · 2021Article
- Stroke Care during the COVID-19 Pandemic: International Expert Panel Review.Cerebrovascular diseases (Basel, Switzerland) · 2021Review
- Association of Optimal Combination Drug Treatment with Obesity Status among Recent Ischemic Stroke Patients: Results of the Vitamin Intervention for Stroke Prevention (VISP) Trial.Journal of stroke · 2017Article
- Baseline Prescription and One-Year Persistence of Secondary Prevention Drugs after an index Stroke in Central Ghana.eNeurologicalSci · 2017Article
- Optimal combination treatment and vascular outcomes in recent ischemic stroke patients by premorbid risk level.Journal of the neurological sciences · 2015Article
- Stroke: Stroke outcomes after 90 days—out of sight, out of mind?Nature reviews. Neurology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveTo investigate the effect of optimal combination of evidence-based drug therapies including antihypertensive agents, lipid modifiers, and antithrombotic agents on risk of recurrent vascular events after stroke.
methodsWe analyzed the database of a multicenter trial involving 3,680 recent noncardioembolic stroke patients aged 35 years or older and followed for 2 years. Patients were categorized by appropriateness level 0 to III depending on the number of drugs prescribed divided by the number of drugs potentially indicated for each patient (0 = none of the indicated medications prescribed and III = all indicated medications prescribed). Independent associations of medication appropriateness level with recurrent stroke (primary outcome), stroke/coronary heart disease/vascular death as major vascular events (secondary outcome), and death (tertiary outcome) were assessed.
resultsThe unadjusted rate of stroke declined with increasing medication appropriateness level (15.9% for level 0, 10.3% for level I, 8.6% for level II, and 7.3% for level III). Compared with level 0: the adjusted hazard ratio of stroke for level I was 0.51 (95% confidence interval, 0.21-1.25), level II 0.50 (0.23-1.09), and level III 0.39 (0.18-0.84); of stroke/coronary heart disease/vascular death for level I 0.60 (0.32-1.14), level II 0.45 (0.25-0.80), and level III 0.39 (0.22-0.69); and of death for level I 0.89 (0.30-2.64), level II 0.71 (0.26-1.93), and level III 0.35 (0.13-0.96).
conclusionsOptimal combination of secondary prevention medication classes after a recent noncardioembolic stroke is associated with a significantly lower risk of stroke, major vascular events, and death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.